Quick Answer
Passage BIO, Inc. reported Diluted EPS of $14.35 per share (loss) for fiscal year 2025.
Passage BIO, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$14.35 | +31.8% |
| 2024 | -$21.04 | -1031.2% |
| 2023 | -$1.86 | +25.6% |
| 2022 | -$2.50 | +28.2% |
| 2021 | -$3.48 | -19.6% |
| 2020 | -$2.91 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$2.44 | +60.3% | +17.6% |
| June 30, 2025 | -$2.96 | +41.8% | -1084.0% |
| March 31, 2025 | -$0.25 | +16.7% | +95.9% |
| September 30, 2024 | -$6.15 | -1155.1% | -20.8% |
| June 30, 2024 | -$5.09 | -1056.8% | -1596.7% |
| March 31, 2024 | -$0.30 | +52.4% | +38.8% |
| September 30, 2023 | -$0.49 | +0.0% | -11.4% |
| June 30, 2023 | -$0.44 | +39.7% | +30.2% |
- Passage BIO, Inc. showed an increase of +31.8% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, Passage BIO, Inc.’s diluted eps has declined by 393.1% (from $2.91 per share (loss) to $14.35 per share (loss)).
- The most recent figure is from Passage BIO, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: